SHL Medical is the pioneering leader in designing, developing, and manufacturing self-injection devices such as autoinjectors.
You have successfully submitted your enquiry. Someone from our company will respond ASAP
SHL Medical is the pioneering leader in designing, developing, and manufacturing self-injection solutions such as autoinjectors, pen injectors, and innovative specialty delivery systems for large-volume and high-viscosity formulations.
We collaborate closely with leading pharmaceutical and biotechnology companies to develop innovative solutions designed to improve patients’ quality of life. By combining cutting-edge science, advanced technologies, and a deep understanding of healthcare needs, we aim to address critical challenges and deliver impactful outcomes.
Our partnerships are rooted in a shared commitment to advancing medical breakthroughs and ensuring that patients worldwide have access to treatments that make a meaningful difference in their lives. We do this with one purpose in mind: Enabling patients’ independence. With a track record of over 60 launched combination products and 40 approved autoinjectors, we deliver proven reliability and quality to our customers, partners, and patients.
In combination product development, pharma and biotech companies have varying device needs based on the drug. Given the breadth of devices we have launched together with our partners, we know how to meet demanding and varied requirements. To do so, we leverage our platform offerings and end-to-end services: from research, and studies to regulatory filings and final assembly. Our integrated approach has been constantly refined over the years to ensure a smooth experience for all partners.
Global team of project and program managers enabling us to meet the growing industry demands.
Sustainability runs through everything we do – from the materials that go into our products to the energy we use. Our goals focus on driving patient health and independence, reducing our ecological footprint, and ensuring responsible business practices.
By putting the patients, the environment, our employees, and the supply chain at the forefront, our 2030 Sustainability Strategy encompasses goals such as:
SHL Medical is a pioneering leader in self-injection solutions, such as autoinjectors. Driven by our core purpose of ‘enabling patients’ independence’, we partner with leading pharma and biotech companies to develop self-injection systems and digital solutions that enhance patients’ treatment experience and quality of life.
With over 5,000 employees located across our offices in Switzerland, the US, Sweden, and Taiwan, we rely on our comprehensive in-house manufacturing capabilities to provide end-to-end services, from design, development, to final assembly, labelling, and packaging.
SHL Medical’s Molly autoinjector is built upon a modular platform technology to address the requirements of our pharma partners, the drug and its primary container, as well as the end users.
In this free white paper, Michael McGowan, senior director of Market Intelligence at SHL Medical, examines the emerging interest in autoinjectors that are capable of delivering higher injection volumes into the subcutaneous space and considers the potential benefits of SHL Medical’s cartridge-based 3ml and 5ml Maggie autoinjectors.
In this free white paper, three of SHL Medical's senior colleagues review how the parenteral space has transformed over the past decade and reports how the company’s portfolio of autoinjector technologies has evolved to deliver subcutaneous parenteral drugs of varying formulations, including higher administration volumes.
In this free white paper, Vince Masciopinto, customer solutions director at SHL Medical, introduces Elexy™, the company’s new reusable electromechanical autoinjector, highlighting the various advantages that the device platform offers at preclinical, clinical and commercial stages due to its ability to deliver a variety of injection profiles from different primary containers without requiring any mechanical reconfiguration of the device.
SHL Medical’s new facility in North Charleston, South Carolina, is expected to start operations by Q2 2024.
SHL Medical, a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedical, a fully integrated contract development and manufacturing organisation (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials.
SHL Medical, a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative speciality delivery systems, has announced the creation of a global alliance management programme with a selection of solutions providers along the drug delivery value chain.
SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, to develop an autoinjector for clinical and potential commercial supply of MoonLake’s Nanobody® sonelokimab based on SHL Medical’s Molly® autoinjector technology.
SHL Medical (hereinafter referred to as 'SHL') has revealed plans for a new manufacturing site in the US, in response to growing market demand for its autoinjector product portfolio. The decision stems from SHL's strategic assessments in extending its production to North America.
On June 22, SHL Medical’s Chief Operating Officer Martin Turvill will be joined by Helbling Business Advisors Partner and Executive Board Member Sébastien Martin in a Quality and Manufacturing Innovation webinar, hosted by the CPhI Podcast Series.
SHL Medical has announced a donation of US$100,000 to help India combat the unprecedented surge of coronavirus infections and support vulnerable communities affected by the pandemic.
SHL will join the 2020 Parenteral Drug Association’s annual Universe of Pre-Filled Syringes and Injection Devices virtual event with the launch of our virtual experience platform.
SHL Medical, a pioneer and technology frontrunner in the self-injection industry, announces its acquisition of Weibel CDS, a medical technology company offering products and solutions for drug delivery and novel packaging.
SHL Medical, a pioneer and technology frontrunner in the self-injection industry, announced its acquisition of Weibel CDS, a medical technology company offering products and solutions for drug delivery and novel packaging.
On 28 January, Innovation Zed, a developer of connected health solutions, entered into a commercial partnership with diagnostics and preventive medicine company A Menarini Diagnostics to market the insulin pen 'InsulCheck Connect' add-on device.
SHL will exhibit at Pharmapack Europe 2020 between 5-6 February in Paris, France.
On 5 November, SHL Group held the inauguration of its new Liufu site in Taoyuan City, Taiwan.
SHL will proudly make its first appearance at the 2019 Partnership Opportunities in Drug Delivery (PODD) Conference on 7-8 October, showcasing at Booth 24, the Renaissance Boston Waterfront Hotel in Boston.
SHL will exhibit at the 2019 Contracting and Outsourcing Conference & Tabletop Exhibition on 26 September in New Brunswick, New Jersey. For this two-day conference, the company is set to showcase its quality offerings in final assembly, labelling and packaging at the one-day tabletop exhibition.
SHL Group is exhibiting at the 2019 BIO International Convention in Philadelphia, Pennsylvania, US.
SHL is primed to exhibit at the Prefilled Syringe Seminar in Tokyo.
SHL Group will lead a webinar titled ‘Personalization of Patient Care – The Next Frontier in Drug Delivery’.
SHL Group has announced that it will make its first appearance at the 21st Asia Pacific League of Associations for Rheumatology Congress.
SHL Group is looking forward to exhibiting at the 2019 Pharmapack, Europe's dedicated pharmaceutical packaging and drug delivery event from 6-7 February in Paris, France.
SHL is set to present its market-leading auto-injector offerings and expertise in final assembly and packaging services at the Drug Delivery Partnerships (DDP) conference this year.
SHL Group will take part in the Universe of Pre-Filled Syringes and Injection Devices conference, which is Parenteral Drug Association’s largest event this year and will take place in October.
SHL Group has announced it will be participating in the BIO International Convention in Boston, Massachusetts, US.
SHL Group has announced it will be exhibiting at the Prefilled Syringe Seminar 2018 in Tokyo.
SHL Group has announced it will hold a live webinar to discuss how pharmaceutical companies can leverage a preconfigured device technology to bring their innovative drug formulations to market more efficiently.
SHL has announced it is exhibiting at the 2018 Drug Delivery Partnerships (DDP) conference in Florida.
With the rapid growth of SHL Group and along with new innovations and technologies developed for pen and autoinjectors, the Taoyuan facility requires expansion of space and thus will be relocating to a new site in Nankan, Taoyuan. Construction started in Q4 of 2015.
SHL Group is pleased to announce a new joint venture (JV) called 'SHL Connect' between SHL Group and ConnectMeSmart.
Molly® 2.25 is a large-volume variant of the Molly autoinjector to accommodate larger-volume biologics. Featuring the same easy-to-use, two-step operation, it inherited the modular platform development model to support high-volume manufacturing, faster development, and flexible design for unique branding needs.
Maggie® is a cartridge-based autoinjector technology built with our market-proven Needle Isolation Technology (NIT®).
Molly® is a single-dose autoinjector technology developed to help pharma and biotech companies reduce initial investments and expedite development timelines.
Maggie® 5.0 is an innovative, large-volume, cartridge-based autoinjector technology built with our market-proven Needle Isolation Technology (NIT®).
Elexy™ is a versatile, electromechanical autoinjector with a reusable power unit compatible with drug cassettes containing a pre-filled syringe or cartridge.
This video gives an overview of SHL Medical's planned production facility in North Charleston, South Carolina.
This video outlines SHL Medical's environmental commitments and the steps it has taken to meet them.
This video outlines how SHL Medical's SLIM technology is designed to enhance medical device assembly.
This video outlines SHL Medical's process of designing and manufacturing an autoinjector.
This video outlines the assembly process using SHL Medical's fully automated assembly machines.
This video provides a short run through SHL Medical's autoinjection device assembly process.
